[ad_1]
This was announced by the Chinese pharmaceutical company Sinopharm, which has developed the two candidates, still in the experimental phase, without providing clinical data to demonstrate their efficacy. “We have not received any comments on serious adverse reactions,” said the president of the company.
Almost a million people in China have received two candidate vaccines against Covid-19, still in the experimental phase. This was announced by the Chinese pharmaceutical company Sinopharm, which has developed them, without providing clinical data to demonstrate their efficacy.
“Our vaccines have been vaccinated to almost one million people and we have received no comment on serious adverse reactions,” Liu Jingzhen, president of Sinopharm, said on the group’s official website.
The company also claims that none of the vaccinated people contracted Covid-19, despite having traveled “to more than 150 countries.”
Covid, China: Four Vaccines in Phase 3 Human Trials
deepening
Coronavirus in Italy and in the world, the latest news. DIRECT
As The Guardian reported, Sinopharm’s two tested vaccines are among the five Chinese candidates currently in international clinical trials.
Four of these vaccines are in phase 3 human trials, the last one before possible approval. In particular, the two candidates developed by Sinopharm are currently being tested (phase 3) in a dozen countries, including the United Arab Emirates, Argentina, Peru, Egypt and Jordan. Additionally, of these four vaccines, at least three candidates have been approved for emergency use outside of clinical trials, and some local governments have reportedly allowed residents to take the Sinovac vaccine. In fact, since last summer, China has allowed the administration of vaccines not yet approved, for cases considered urgent, such as employees and students traveling abroad, or even particularly exposed workers, such as nurses.
Anti-Covid Vaccine, EU: Modern and Pfizer May Go Green by the End of the Year
There is also encouraging news from the vaccine candidates developed by BioNTech-Pfizer and Moderna. On November 19, the President of the European Commission Ursula Von der Leyen at the end of the videoconference with EU leaders announced that the European Medicines Agency (EMA) could give the authorization for the marketing of the vaccines BioNTech-Pfizer and Moderna in the second half of December, “if all goes well.” “We have learned from the experience of this summer that getting out of a wave is difficult, and if one is quick to relax the measures there is a very negative impact on the epidemiological situation. We have to manage things properly, “said Von der Leyen.” We will make a proposal for a gradual and coordinated approach to make containment measures more flexible, this to avoid the risk of another wave, “he added, specifying that” a vaccination campaign is being worked on, supporting member states in the importance of vaccines. It means protecting yourself, it’s a question of solidarity.
